Advamedica

Executive Summary

Advamedica is a US-based medical device company specializing in biomaterial-based solutions for bleeding control and wound care. Founded in 2010 and headquartered in San Diego, the company targets pre-hospital, intra-operative, and post-operative settings to improve patient outcomes. Its core technology platform enables the development of hemostatic, surgical, and wound care products. With a focus on novel biomaterials, Advamedica addresses critical needs in cardiovascular and general surgery, aiming to reduce bleeding complications and enhance recovery. The company is privately held with no disclosed funding or valuation, but its positioning in the high-demand hemostatic market suggests potential for growth. Key differentiators include its proprietary biomaterial platform and focus on acute care scenarios. However, limited public data on clinical progress or commercial traction makes it a higher-risk opportunity. The company's ability to secure FDA clearances and establish partnerships will be crucial for near-term success.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for a novel hemostatic device60% success
• Q4 2026Clinical trial results for wound care product50% success
• H2 2026Strategic partnership or distribution agreement65% success